How Risankizumab Helps People with Psoriasis

Psoriasis is a challenging skin condition characterized by red, scaly patches that can significantly impact quality of life. A new drug, risankizumab, has been approved to treat moderate-to-severe plaque psoriasis by targeting specific immune system pathways that cause inflammation.

Updated Guidelines

The International Psoriasis Council (IPC) has expanded its guidelines for systemic therapy to include:

• Individuals with more than 10% body surface area affected
• Those with lesions in sensitive areas
• Patients who have not responded to topical treatments

Study Findings

A recent study evaluated risankizumab's effectiveness in real-world settings, focusing on:

1. Group 1: 3-10% body surface area affected
2. Group 2: Meets IPC criteria for systemic therapy

Key Results:

• Risankizumab proved effective in both groups.
• Highlights potential benefits for less severe cases, not just severe ones.
• Emphasizes the importance of personalized medicine in psoriasis treatment.

Future Considerations

While promising, more research is needed to:

• Understand long-term effects
• Compare risankizumab with other treatments

For now, risankizumab offers hope for better symptom management and improved quality of life for psoriasis patients.